| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
Neoisoastilbin does not have a defined biological target but exhibits multiple biological activities. It possesses antioxidant, anti-hyperuricemic, and anti-inflammatory properties. Neoisoastilbin inhibits RSL3-induced ferroptosis and can be used to study colorectal cancer. Its antioxidant and anti-inflammatory activities are evaluated by radical scavenging assay, reducing power determination, and lipopolysaccharide (LPS)-induced RAW264.7 cell assays.
|
|---|---|
| ln Vitro |
In vitro, neoisoastilbin exhibits antioxidant and anti-inflammatory activities. Its antioxidant activity is evaluated by radical scavenging assay (DPPH and ABTS) and reducing power determination. It possesses significant suppression effect on proinflammatory mediators production, such as nitric oxide (NO), tumor necrosis factor-α (TNF-α), and interleukin-6 (IL-6), in LPS-induced RAW264.7 cells. Neoisoastilbin also inhibits RSL3-induced ferroptosis.
|
| ln Vivo |
Neoisoastilbin is not a pharmacologically approved drug and does not have established in vivo therapeutic activity. It has been studied for its potential anti-inflammatory, antioxidant, and immunomodulatory effects, making it a valuable compound in the treatment of inflammatory and autoimmune diseases. The compound has not been evaluated in clinical trials. It is a research compound used to study inflammation and oxidative stress.
|
| Enzyme Assay |
In vitro assays for neoisoastilbin typically involve antioxidant and anti-inflammatory activity measurements. For antioxidant activity, a standard protocol involves incubating the compound with DPPH or ABTS radicals and measuring the reduction in absorbance spectrophotometrically. For anti-inflammatory activity, RAW264.7 macrophages are treated with lipopolysaccharide (LPS) in the presence of varying concentrations of neoisoastilbin (typically 1-100 µM). Nitric oxide production is measured by the Griess assay, and cytokine levels (TNF-α, IL-6) are measured by ELISA.
|
| Cell Assay |
In vitro cell culture experiments with neoisoastilbin typically involve RAW264.7 macrophages. Cells are cultured in appropriate media and treated with the compound at concentrations ranging from 1-100 µM for 24-48 hours. LPS (typically 1 µg/mL) is added to stimulate inflammation. Cell viability is assessed using MTT assays to ensure that observed effects are not due to cytotoxicity. Nitric oxide production is measured by the Griess assay, and cytokine levels are measured by ELISA.
|
| Animal Protocol |
In vivo animal studies with neoisoastilbin are not well documented, as it is primarily a research compound. If conducted, typical protocols for anti-inflammatory studies would involve administering the compound to animal models of inflammation (e.g., carrageenan-induced paw edema or colitis models). However, such studies are not standard for this compound.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of neoisoastilbin are not characterized, as it is not a drug substance. Based on its physicochemical properties (molecular weight 450.39, soluble in DMSO at 55 mg/mL), the compound would be expected to have moderate oral bioavailability. The compound should be stored at low temperature, protected from direct sunlight.
|
| Toxicity/Toxicokinetics |
Neoisoastilbin may cause skin and eye irritation. Standard laboratory safety precautions should be followed when handling this compound, including the use of gloves, safety glasses, and working in a fume hood. The compound should be stored in a cool, dry place away from light and moisture. No acute toxicity data are available. The compound is not intended for drug, household, or other uses.
|
| References | |
| Additional Infomation |
Astilbin is a flavanone glycoside formed by the substitution of (+)-taxanthin at the 3-position by an α-L-rhamnosyl group via a glycosidic bond. It possesses free radical scavenging, anti-inflammatory, and plant metabolite activity. It is an α-L-rhamnosyl glycoside belonging to the 3'-hydroxyflavanone, tetrahydroxyflavanone, flavanone glycoside, monosaccharide derivative, and 4'-hydroxyflavanone classes. Functionally, it is related to (+)-taxanthin. It is the enantiomer of neoAstilbin. Astilbin has been reported in Neolitsea aurata, Hymenaea martiana, and other organisms with relevant data. Astilbin is a metabolite found or produced in Saccharomyces cerevisiae.
Neoisoastilbin is a flavonoid glycoside and an isomer of astilbin. It possesses antioxidant, anti-hyperuricemic, and anti-inflammatory activities. It is a valuable compound in the treatment of inflammatory and autoimmune diseases. Neoisoastilbin has not undergone clinical trials and is not approved as a pharmaceutical. |
| Molecular Formula |
C21H22O11
|
|---|---|
| Molecular Weight |
450.39
|
| Exact Mass |
450.116
|
| CAS # |
54141-72-9
|
| PubChem CID |
119258
|
| Appearance |
Off-white to light yellow solid
|
| Density |
1.74g/cm3
|
| Boiling Point |
801.1ºC at 760mmHg
|
| Melting Point |
179 - 180 °C
|
| Flash Point |
282.9ºC
|
| Index of Refraction |
1.748
|
| LogP |
0.038
|
| Hydrogen Bond Donor Count |
7
|
| Hydrogen Bond Acceptor Count |
11
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
32
|
| Complexity |
676
|
| Defined Atom Stereocenter Count |
7
|
| SMILES |
O1[C@@]([H])(C([H])([H])[H])[C@@]([H])([C@]([H])([C@]([H])([C@]1([H])O[C@@]1([H])C(C2=C(C([H])=C(C([H])=C2O[C@@]1([H])C1C([H])=C([H])C(=C(C=1[H])O[H])O[H])O[H])O[H])=O)O[H])O[H])O[H]
|
| InChi Key |
ZROGCCBNZBKLEL-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C21H22O11/c1-7-15(26)17(28)18(29)21(30-7)32-20-16(27)14-12(25)5-9(22)6-13(14)31-19(20)8-2-3-10(23)11(24)4-8/h2-7,15,17-26,28-29H,1H3
|
| Chemical Name |
2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-3-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxy-2,3-dihydrochromen-4-one
|
| Synonyms |
Neoisoastilbin
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 100 mg/mL (222.03 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (5.55 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (5.55 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (5.55 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.2203 mL | 11.1015 mL | 22.2030 mL | |
| 5 mM | 0.4441 mL | 2.2203 mL | 4.4406 mL | |
| 10 mM | 0.2220 mL | 1.1101 mL | 2.2203 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
|
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
